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Stabilization of the blood-brain barrier during and after stroke can lead to less adverse
outcome. For elucidation of underlying mechanisms and development of novel therapeutic
strategies validated in vitro disease models of the blood-brain barrier could be very
helpful. To mimic in vitro stroke conditions we have established a blood-brain barrier
in vitro model based on mouse cell line cerebEND and applied oxygen/glucose deprivation
(OGD). The role of astrocytes in this disease model was investigated by using cell line
C6. Transwell studies pointed out that addition of astrocytes during OGD increased the
barrier damage significantly in comparison to the endothelial monoculture shown by
changes of transendothelial electrical resistance as well as fluorescein permeability data.
Analysis on mRNA and protein levels by qPCR, western blotting and immunofluorescence
microscopy of tight junction molecules claudin-3,-5,-12, occludin and ZO-1 revealed that
their regulation and localisation is associated with the functional barrier breakdown.
Furthermore, soluble factors of astrocytes, OGD and their combination were able to induce
changes of functionality and expression of ABC-transporters Abcb1a (P-gp), Abcg2 (bcrp),
and Abcc4 (mrp4). Moreover, the expression of proteases (matrixmetalloproteinases
MMP-2, MMP-3, MMP-9, and t-PA) as well as of their endogenous inhibitors (TIMP-1,
TIMP-3, PAI-1) was altered by astrocyte factors and OGD which resulted in significant
changes of total MMP and t-PA activity. Morphological rearrangements induced by
OGD and treatment with astrocyte factors were confirmed at a nanometer scale using
atomic force microscopy. In conclusion, astrocytes play a major role in blood-brain barrier
breakdown during OGD in vitro.
Keywords: blood-brain barrier, in vitro, stroke, oxygen/glucose deprivation, ischemia, traumatic brain injury,
cerebEND, C6
INTRODUCTION
Impairment of the blood-brain barrier (BBB) leads to vasogenic
edema and subsequent brain damage after acute cerebral ischemic
insults such as stroke or traumatic brain injury. Reduced per-
meability of the BBB is associated with decreased harm and
improved outcome after stroke (Yang and Rosenberg, 2011).
Consequently, elucidation of underlying mechanisms causing
BBB breakdown may lead to novel targets for future treatments
to reduce adverse stroke outcomes. The BBB itself is considered
as the most important interface between blood circulation and
the central nervous system (CNS). Physiological roles of the BBB
are to maintain the homoestasis in the CNS, to prevent the pas-
sage of bacteria, viruses and unwelcomed substances into the
CNS and to efflux CNS waste products. In the 1960’s Reese and
Brightman found out by electron microscopy that the brain cap-
illary endothelium is the main component of the BBB, which is
sealed by intercellular tight junctions. In addition to the presence
of tight junctions further major differences of the brain capillary
endothelium in comparison to the peripheral endothelium is the
lack of fenestrae and reduced pinocytotic activity (Brightman
and Reese, 1969; Joo, 1996). During ischemia several key prop-
erties of the BBB are changed. The physical barrier is disrupted
which results in increased permeability for marker molecules of
the paracellular route such as albumin bound Evans blue, flu-
orescent labeled dextrans, fluorescein, mannitol, and sucrose.
This loss of barrier function against hydrophilic compounds was
associated with alterations within the tight junctional complex
reflected by decreased expression or delocalisation of tight junc-
tion proteins such as occludin (András et al., 2007; Kleinschnitz
et al., 2011). Furthermore, changed expression and functional-
ity of ATP-binding cassette (ABC)-transporter proteins such as
P-glycoprotein (P-gp or Abcb1) and breast cancer resistance pro-
tein (bcrp or Abcg2) were reported under ischemic or hypoxic
conditions. One of the consequences would be an altered trans-
port barrier accompanied with a loss of the protective function
against a wide array of xenobiotics. In addition, the activity of
proteases such as matrixmetalloproteinases (MMPs) and tissue-
plasminogen activator (t-PA) is increased during stroke that was
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shown to be associated with degradation of the basal lamina and
integrity loss of the BBB (reviewed in Jin et al., 2010 and Patak
and Hermann, 2011).
Nowadays, the BBB is understood as a complex regulated sys-
tem. Terms such as neuro- or gliavascular unit (NVU, GVU)
describe the strong influence of the microenvironment on the
brain endothelium. Neighboring cell types such as astrocytes, per-
icytes, microglia or even neurons are known to influence the
functionality of the BBB in health as well as in disease, which
is supported by their physical proximity and consequent small
diffusion distances for signaling molecules (Abbott et al., 2006;
Cecchelli et al., 2007). During ischemia the undersupply with
glucose and oxygen causes reduced ATP production and loss of
available energy at the NVU. This contributes significantly to the
breakdown of the BBB (Ronaldson and Davis, 2012). Therefore,
application of oxygen/glucose deprivation (OGD) on CNS cells
in vitro is an established model for stroke. Recent studies showed
that BBB in vitro models based on brain endothelial cells co-
or even triple-cultured with astrocytes and/or pericytes are able
to reflect the physiology of the BBB in a more accurate manner
(Török et al., 2003; Nakagawa et al., 2009; Ceruti et al., 2011).
In this context, in case of in vitro stroke models of the BBB,
lately reports confirmed that astrocytes aggravated the break-
down of the physical barrier (Mysiorek et al., 2009). However,
underlying mechanisms were not described in detail and the
need to investigate and understand them seemed to be essen-
tial for validation purposes. In previous studies, we have applied
and optimized oxygen/glucose deprivation (OGD) conditions for
brain endothelial mono-cultures to mimick stroke in vitro and to
study molecular mechanisms lying behind the successful, func-
tional stabilization of the BBB in vivo during stroke or traumatic
brain injury (Kleinschnitz et al., 2011; Neuhaus et al., 2012a; Thal
et al., 2013). The aim of the present study was to extend our
stroke in vitromodels of the BBB with astrocytes by co-cultivation
of mouse BBB cell line cerebEND with rat cell line C6 and to
investigate the influence of astrocytes under OGD-conditions on
several BBB relevant parameters such as functionality of the phys-
ical as well as transport barrier, associated tight junctionmolecule
and Abc-transporter expression, expression and functionality of
MMPs, t-PA and of their endogenous inhibitors, and last but not
least whether morphological changes were detectable via atomic
force microscopy.
MATERIALS AND METHODS
MATERIALS
Collagen IV from human placenta (C5533), PBS (D8537),
Triton-X 100 (T8787), DMEM (D5796), Calcein-AM (17783),
DAPI (D8417), db-cAMP (D0260), MK571 (M7571), Ko143
(K2144), verapamil.HCl (V4629), β-mercaptoethanol (M6250),
fluorescein sodium (F6377), albumin from bovine serum for
immunofluorescence microscopy (fraction V, A9647) and for
western blotting (A7906) were purchased from Sigma-Aldrich.
Bodipy-FL-prazosin (B-7433), DMEM without glucose (11966-
025, Gibco®) was obtained from Life technologies (USA), and
fluo-cAMP (F002-01) was from Biolog (Bremen, Germany). FCS
Gold EU approved was bought from PAA Laboratories (A15151,
Lot A15111-2018, Linz, Austria) and was heat-inactivated
in a water-bath at 56◦C for 30min. Penicillin/streptomycin
(100X, 10,000 Units/mL, 10,000μg/mL, A2213) and 0.05%
Tyrpsin/0.02% EDTA-solution (L2143) were from BioChrom AG
(Berlin, Germany). 6-well, 12-well and 24-well plates and 24-well
Transwell® inserts (0.4μm pore size, PET) were obtained from
Becton and Dickinson (REF353046, REF353043, REF353095,
REF353226, USA). Gelatine was from SERVA (22151, Heidelberg,
Germany), nuclease-free water was purchased from Ambion
(AM9937, USA). All other substances were of analytical grade.
CELL CULTURE
Mouse brain endothelial cell line cerebEND was produced from
isolated brain microvascular endothelial cells from cerebellum
by Silwedel and Förster (2006). cerebENDs were cultured in
DMEM medium supplemented with 10% FCS and 1% peni-
cillin/streptomycin in 0.5% gelatine coated cell culture tissue
flasks and were subcultivated by trypsination in a ratio of 1:3
once a week as published recently (Neuhaus et al., 2012a). Rat
glioma cell line C6 was obtained from ATCC and cultured with
the same medium as cerebENDs in 0.5% gelatine coated cell cul-
ture tissue flasks. Subcultivation was accomplished in a ratio of
1:20 once a week. Cells were maintained in an incubator at 37◦C,
95% humidity and a 5% CO2/95% air atmosphere.
TRANSWELL EXPERIMENTS
24-well plate inserts were coated with 100μg/mL collagen IV (dis-
solved in acetic acid according to the manufacturer’s instruction)
at RT for 2 h and were washed with PBS for three times to get
rid off the residual acetic acid. CerebENDs were seeded at a den-
sity of 40,000 cells/cm2 on the 24-well inserts, and every other
day growth medium was renewed. On day 7 after seeding apical
growth medium was supplemented with 100 nM hydrocortisone
(100μM stock dissolved in ethanol) and C6 cells were seeded at a
density of 20,000 cells/cm2 in 0.5% gelatine coated 24-well plates.
On day 9 inserts with cerebENDs were placed over C6 cell con-
taining well-plates to form the co-culture set-up still with 100 nM
hydrocortisone in the apical chamber. The Transwell insert culti-
vation procedure was summarized in Figure 1S. Oxygen/glucose
deprivation (OGD) experiments were conducted on day 13.
cerebEND cells in inserts and C6 cells in well-plates were washed
with PBS twice before they were reesembled and serum-free
DMEM with or without glucose was added. Transendothelial
electrical resistance (TEER) was measured using chopstick elec-
trodes from Millipore after 30min of equibrilation at RT as pre-
viously published (Neuhaus et al., 2006). To apply OGD, cells in
serum-free DMEM without glucose were incubated in a hypoxia
incubator (HERACELL 150i, ThermoFisher, USA) with 1% O2,
5% CO2, saturated humidity atmosphere and 37◦C for 4 h. As
controls, blank inserts without cells, mono-cultured cerebEND
cells and cerebENDs co-cultured with C6 cells were incubated in a
normoxia incubator at air O2, 5%CO2, saturated humidity atmo-
sphere and 37◦C for the same time. After incubation TEER was
measured again after a 30min temperature equibrilation phase.
To study fluorescein permeability of cell layers, apical experimen-
tal medium was exchanged with 300μL DMEM with or without
glucose containing 10μM fluorescein and transport study was
accomplished for 1 h at 37◦C under normoxic conditions. DMEM
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with or without glucose as blank solutions, basolateral samples
and residual apical stock solutions were measured in 100μL trip-
licates in black 96-well plates (GreinerBioOne, Kremsmünster,
Austria) with a fluorescence microplate reader (GeniosPro, Tecan,
Austria) at 485/535 nm (excitation/emission wavelength). TEER
in Ohm/cm2 and permeability coefficients including blank insert
values were calculated as previously published (Neuhaus et al.,
2008; Novakova et al., 2014). Due to comparison reasons, val-
ues of normoxic mono-cultured cerebEND controls were set
to 100%.
QUANTITATIVE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN
REACTION (qPCR)
For qPCR experiments, cerebEND and C6 cells were seeded in
gelatine (0.5%, Serva, Germany) coated 6-well plates at a den-
sity of 40,000 cells/cm2 or 20,000 cells/cm2, respectively. Every
other day growth medium was renewed. On day 6 after seed-
ing, cells were washed with PBS twice, and 3mL of serum-
free DMEM with or without glucose was added, and normoxia
or OGD treatment was applied for 4 h as described above.
Four different kinds of treatments were conducted: N = nor-
moxia, OGD = oxygen/glucose deprivation, N-C6 = normoxia
of cerebEND cells with supernatant of normoxic treated C6 cells
and OGD-C6 = oxygen/glucose deprivation of cerebEND cells
with supernatant of OGD-treated C6 cells. In case of N-C6
and OGD-C6 treatments, C6 cells were incubated for 4 h nor-
moxia or OGD to obtain their supernatants which were directly
applied on PBS washed cerebEND cell layers to guarentee fresh
soluble factors of C6 cells for further 4 h incubation. After N,
N-C6, OGD or OGD-C6 treatment of cerebEND cells experi-
mental media were removed and lysed in RA1 buffer (supple-
mented with 1% β-mercaptoethanol shortly before usage) of the
Nucleospin-RNAII Kit (Macherey Nagel, Düren, Germany). Total
RNA was isolated using the Nucleospin-RNAII Kit according to
the manufacturer’s instruction as described before in Neuhaus
et al. (2012b). RNA concentrations were determined by means
of a Nanodrop ND 2000 spectrophotometer (FisherScientific,
Schwerte, Germany) at 260/280 nm. 1μg total RNA per sample
were reversely transcribed to 20μL cDNA by means of the high
capacity cDNA-kit (with random primer and RNAse inhibitor)
from Applied Biosystems (Life Technologies GmbH, Darmstadt,
Germany) according to the manufacturer’s instruction. qPCR
analysis were performed using FAM-labeled probes for all investi-
gated targets (Taqman®, Applied Biosystems) as recently reported
(Neuhaus et al., 2012b). A detailed list with the product numbers
of Taqman®-probes could be found in the Supplementary part
(Table 1S). Each sample was analyzed as triplicate. RelativemRNA
abundances to β-actin were calculated by the ddCt method using
following formula: 2(Ct of β-actin-Ct of gene of interest), where Ct is the
threshold cycle value.
WESTERN BLOTTING
Cells were cultured as described above under Section Quantitative
Reverse-Transcriptase Polymerase Chain Reaction (qPCR) and
scraped after the treatments in 50μL RIPA buffer per 6-
well [50mM TRIS pH 8; 150mM NaCl, 0.1% SDS, 0.5%
sodium-deoxycholate, 1% NP40 supplemented with one
complete ULTRA protease inhibitor cocktail and PhosphoSTOP
minitablet per 10mL (complete ULTRA tablets, Mini, EASYpack,
REF05892970001; PhosSTOP, REF04906837001, Roche Applied
Science, Mannheim, Germany)] on ice after washing with ice-
cold PBS twice as described previously (Neuhaus et al., 2012b).
In case of membran protein enrichment, proteins were extracted
with 1% Triton-X 100 in PBS (supplemented with one complete
ULTRA protease inhibitor cocktail and PhosphoSTOP minitablet
per 10mL) gentle shaking at 4◦C for 30min after washing
with ice-cold PBS on ice twice. Sample’s protein concentrations
were determined by a detergent-compatible Pierce BCA assay
(FisherScientific) utilizing a BSA standard curve (Albumin
Standard, FisherScientific). Before storage at −80◦C 4x Laemmli
buffer (8% SDS, 40% glycerol, 0.004% bromphenolic blue,
0.25M Tris-HCl supplemented with 6% β-mercaptoethanol
shortly before usage) was added to the samples. 20μg protein
of total RIPA-cell lysates and 15μg of Triton-X 100 fractions
per lane and peqGOLD prestained protein marker V (PEQLAB)
were loaded onto 7.5, 10 or 12% SDS-PAGE gels (1.5mm thick)
after ultrasound treatment and 5min denaturation at 70◦C.
After gel electrophoresis at 130V, proteins were immunoblotted
onto polyvinylidene difluoride membranes (162–0177, Biorad,
München, Germany) by a tank blotter at 40mA per gel at 4◦C
overnight. Incubations with primary and secondary antibod-
ies were carried out as previously described (Neuhaus et al.,
2012b). Used primary and secondary antibodies are listed in the
Supplementary Table 2S. To visualize the bands, western blots
were incubated with ECL-solutions for 3min and were devel-
oped using a FluorChem FC2 Multiimager II (Alpha Innotech,
Hessisch Oldendorf, Germany). Density values of single protein
bands were calculated with the software Alpha View and were
related to the corresponding β-actin bands. In some cases,
antibodies onto western blots were stripped by washing with
H2O dest. for 5min followed by a treatment with 0.2M NaOH
for 5min and a second washing step with H2O dest. for 5min.
After an additional washing step with PBS-T, membranes were
blocked with 5% milk powder before reprobing with the next
primary antibody. In case of strong antibody-protein binding,
antibodies were stripped by washing 10min with PBS-T for
three times and incubated with a 100mM ß-mercaptoethanol
containing buffer (62.5mM Tris-HCl pH = 6.8, 2% SDS, freshly
added ß-mercaptoethanol) at 56◦C and gentle shaking for 20min
followed by three washing steps with PBS-T each for 10min.
Finally, membranes were blocked with 5%milk powder as before.
IMMUNOFLUORESCENCE MICROSCOPY
Immunofluorescence microscopy was carried out as published
recently (Neuhaus et al., 2008, 2012b). In brief, cerebEND cell
layers (cultured as explained above on 15mm, with ethanol
disinfected, PBS washed and collagen IV coated glas slides in
12-well plates) were washed for three times with PBS and fixed
and permeabilized with precooled MeOH at −20◦C for 20min.
After washing with PBS twice, cells were rehydrated with PBS at
RT for 15min. In case of staining with the mouse anti-occludin
antibody, cells were fixed with ice-cold ethanol incubated at
−20◦C for 20min followed by −20◦C cold acetone at room
temperature for 3min and drying after acetone removal at room
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temperature for 10min. Then, cell layers were incubated with
primary antibody solutions (see Supplementary Table 2S) at 37◦C
for 1 h. After washing for three times with PBS cell layers were
incubated with 1:100 1% BSA/PBS solutions with the secondary
antibodies (see Supplementary Table 2S) at 37◦C for 30min.
For nuclei staining an additional incubation step of 10min at
37◦C with 1:3000 of 5mg/mL DAPI in PBS was carried out. After
washing with PBS for three times, cover slips were transferred to
glas slides and were embedded in Vectashield Hard-Set mounting
medium (Vector Laboratories LTD., Peterborough, United
Kingdom). Images were generated by using an Olympus BX51
microscopy system using UPlan FLN objectives (4x/0.13/∞/-
/FN26.5; 10x/0.30//∞/-/FN26.5; 20x/0.50/∞/0.17/FN26.5;
40x/0.75/∞/0.17/FN26.5; 60x/0.90/0.11-0.23/FN26.5) equipped
with U-RFL-T laser and controlled by the software cellSense
Dimension.
UPTAKE ASSAYS
cerebEND cells were seeded in 200μL growth medium at a den-
sity of 40,000 cells/cm2 in clear, gelatine (0.5%) coated 96-well
plates (GreinerBioOne, Kremsmünster, Austria). On day 6 after
seeding, cells were washed with 200μL prewarmed HBSS per
96-well twice and incubated in 100μL appropriate medium for
4 h. For normoxia (N) serum-free DMEM containing glucose, for
OGD serum-free DMEM without glucose, for N-C6 sterile fil-
tered, serum-free DMEM with glucose preincubated on washed
C6 cell layers over night and for OGD-C6 sterile filtered, serum-
free DMEM without glucose preincubated on washed C6 cell lay-
ers under OGD conditions over night were used. In case of OGD
and OGD-C6 with cerebEND cells, medium was changed after
4 h of incubation in the hypoxia chamber to normoxic or N-C6
medium (i.e., serum-free DMEM with glucose or sterile-filtered,
serum-free DMEM with glucose preincubated with C6 cells over
night) for further 20 h in the normxia chamber to simulate reoxy-
genation/renutrition. After 24 h of incubation in total, medium
in selected wells was changed with 100μL appropriate exper-
imental media containing specific ABC-transporter inhibitors
[Abcb1: 100μM verapamil (100mM stock in DMSO), Abcc4:
10μM MK571 (10mM stock in DMSO), 100–500μM db-cAMP
(100mM stock in H2O), Abcg2: 5μM Ko143 (5mM stock in
DMSO)] for 15–30min preincubation at 37◦C. After that, uptake
of specific substrates (end concentrations: 1μM calcein-AM for
Abcb1, 10μMfluo-cAMP for Abcc4 (Reichel et al., 2010), 0.5μM
Bodipy-FL-prazosin for Abcg2) was started by addition of 100μL
of appropriate experimental media containing 2-fold substrate
concentrations and in case additionally one-fold inhibitor con-
centration. Stock solutions of substrates (1mM Calcein-AM in
DMSO, 2mM fluo-cAMP in H2O, 500μM Bodipy-FL-prazosin
in DMSO) were thawed in darkness shortly before addition to
ice-cold experimental media prepared in darkness to prevent
degradation of light-sensitive substrates. After 45 (Abcb1), 90
(Abcc4) or 120 (Abcg2) minutes of incubation at 37◦C, cells were
washed on ice with 200μL/well ice-cold HBSS for three times and
lysed with 1% Triton-X 100 solution (in HBSS) for at least 1 h
during gently shaking in darkness. Then, fluorescence of uptaken
substrates wasmeasured at 485/535 nm excitation/emission wave-
length by means of a fluorescence microplate reader (GeniosPro,
Tecan, Austria), substracted by background fluorescence of cells
and related to their protein concentration determined by BCA
method as described above in Section Western Blotting. Control
wells after 24 h of normoxia were set to 100% and effects of
added inhibitors under each condition were calculated. Changes
of efflux functionality were presented as differences in inhibitor
dependent uptake percentages in order to minimize the influ-
ence of other unkown, possibly regulated transporters on the total
uptake of the used substrates. Prelimenary tests with used trans-
porter inhibitors verapamil (Abcb1), MK571 (Abcc4) and Ko143
(Abcg2) confirmed their specificity for investigated transporters
in cerebEND cells (see Supplementary Figure 2S).
MEASUREMENT OF ENZYME ACTIVITIES
To measure enzyme activity of matrixmetalloproteinases (MMP)
or of tissue plasminogen activator (t-PA), medium supernatants
of cerebENDs after N, N-C6, OGD or OGD-C6 treatments or
C6 cells after N or OGD treatment were collected and stored
at −80◦C until measurement. 6mL medium pooled from two
six-wells were concentrated to 200μL by centrifugation at 4000 g
and 4◦C for 40min using 10 kDa Amicon ultrafiltration tubes
(UFC901024, Millipore, Germany). In case of MMP activity,
80μL of retentates were mixed with 50μL of 1:10 diluted MMP
substrate with assay buffer (520 MMP FRET substrate SB-14,
100μM stock dissolved in 10% DMSO in assay buffer, 60581-
01, Anaspec, USA) in a black 96-well microplate (GreinerBioOne,
Kremsmünster, Austria). TheMMP substrate is sensitive to detect
activity of MMP-1, -2, -3, -7, -8, -9, -12, and -13. Increasing flu-
orescence was recorded over 120min at 37◦C and 485/535 nm in
a microplate reader (GeniosPro, Tecan, Austria). Control blank
values with pure DMEM were substracted from MMPs contain-
ing media and slopes between 10 and 60min were calculated
after linear regression analysis. Values were corrected for minor
deviations of obtained retentat volumina after the centrifugation
before. Slopes of media supernatants of cerebEND cells treated
for 4 h of normoxia (N) were set to 100%. In case of t-PA activity,
80μL of retentats were mixed with 50μL of 1:100 diluted t-PA
substrate with assay buffer (component A of Sensolyte AMC t-
PA activity assay kit, 72160, Anaspec, USA) in a black 96-well
microplate and fluorescence was recorded over 120min at 37◦C
and 360/460 nm in a microplate reader. Control blank values
with pure DMEM were substracted from t-PA containing media
and slopes between 10 and 120min were calculated after linear
regression analysis. Values were corrected for minor deviations
of obtained retentat volumina after the centrifugation before.
Slopes of media supernatants of cerebEND cells treated for 4 h
of normoxia (N) were set to 100%.
SURFACE NANO-TEXTURE ANALYSIS (nAnostic)
Contact mode Atomic forcemicroscopy (AFM) on cultivated cells
was performed as described before (Jungmann et al., 2008). In
this study, cells were chemically stabilized by glutardialdehyde fix-
ation (1% final concentration). Briefly, AFM measurements were
carried out in PBS-buffered solution (pH 7.4) using a Multimode
AFM equipped with Nanoscope III controller and software ver-
sion 5.30sr3 (Digital Instruments, Santa Barbara, CA, USA).
Silicon-nitride tips on V-shaped gold-coated cantilevers were
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used (0.01N/m, MLCT, VEECO, Mannheim, Germany). Imaging
was performed at ambient temperature with forces less than 1 nN
at 1–3 scan lines per second (1–3Hz) with 512∗512 pixels resolu-
tion. For texture analysis, subcellular scan areas of (20μm)2 are
recorded. Topographical data of the cell surfaces were analyzed
using the nAnostic™-method applying custom-built, proprietary
algorithms (Serend-ip GmbH, Münster, Germany). The method
principle has been described before (Thoelking et al., 2010).
Briefly, each nanostructure protruding from the mean surface
level is morphometrically evaluated. Then, they are filtered by
their size and shape through computer vision; here, only struc-
tures of positive local deviational volume (LDV), with LDV less
than 1 cubed μm (103 nm height, 103nm∗103nm area) were con-
sidered. The average volume of thousands of objects analyzed
per sample was 0.0021μm3. Values are given for the count of
such objects (per 20μm image). Ten (20μm)2 areas per slide
were arbitrarily chosen and evaluated from two independent
experiments. To comply with inbuilt biological heterogeneity
the number of analyzed areas was set to n = 20 for statistical
significance.
RESULTS
ASTROCYTES INCREASE OGD-INDUCED DAMAGE OF THE
BLOOD-BRAIN BARRIER
Based on preliminary experiments and literature data of OGD-
treated murine brain endothelial cells (Kleinschnitz et al., 2011),
it was decided to concentrate on 4 h OGD-treatments with
1% O2 in glucose-, and serum-free medium. Prior studies
showed that cerebENDs reacted on 4 h OGD-treatment with
significant upregulation of HIF1α (1.5-fold) and VEGFa (11-14-
fold) (Supplementary Figure 3S, further targets angiopoietin-2,
caveolin-1, Lrp-1, neuropilin-1 and Tie-2 see Supplementary
Table 3S), while cell viability remained unaffected (Neuhaus
et al., 2012a). Differences of electrical resistance raw data
between cell and blank inserts in serum-free media before OGD-
treatment were in average about 80–82 for mono-cultured
and 62–63 for cerebENDs co-cultured with C6 cells result-
ing in calculated TEER values in average of 250/cm2 or
200/cm2, respectively. Measuring changes of TEER before
and after OGD-treatment revealed no significant decrease of
TEER of mono-cultured cerebEND layers [100 ± 12% nor-
moxia (n = 42) vs. 98 ± 16% OGD (n = 11)] (Figure 1A).
On the contrary, comparison of cerebENDs co-cultivated with
C6 cells showed a significant increase in TEER to 117 ± 20%
(p < 0.05, n = 24) after 4 h serum-free normoxia and a signif-
icant decrease to 61 ± 23% (p < 0.05, n = 59) after 4 h OGD
treatment. Data of fluorescein permeability studies under nor-
moxic conditions after TEER measurement—equivalent with a
1 h reoxygenation phase—confirmed the deleterious effects of
C6 cells on tightness of cerebEND cell layers during OGD,
but also uncovered harmful effects of OGD on mono-cultured
cerebENDs (Figure 1B). In detail, fluorescein permeability was
significantly increased by OGD to 152 ± 31% (p < 0.05, n = 11)
in comparison to normoxic controls (100 ± 20%, n = 31). In
case of C6 co-cultered cerebENDs, fluorescein permeability was
131 ± 21% (n = 18) under normoxic conditions in compari-
son to the normoxic mono-cultured cerebEND layers and was
FIGURE 1 | Influence of 4h oxygen/glucose deprivation (OGD)
treatment on barrier functionality of mono-cultured cerebEND layers
or co-cultured with astrocytes (C6) on Transwell inserts measured by
TEER (A) or fluorescein permeability (B). Statistical significance was
labeled with ∗(p < 0.05, two-sided student’s t-test with same variances).
Data are presented as means ± SD (n = 11–59).
significantly elevated to 242± 61% by OGD treatment (p < 0.05,
n = 50).
INFLUENCE OF ASTROCYTES AND OGD ON EXPRESSION OF TIGHT
JUNCTION PROTEINS
First, influence of astrocytes and OGD on mRNA levels of
claudin-3, claudin-5, claudin-12, occludin and ZO-1 was mea-
sured by qPCR (Table 1). Claudin-3 was only downregulated by
addition of astrocyte factors (73%, p < 0.05). In case of claudin-
5, it was significantly downregulated by OGD and OGD-C6 to
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Table 1 | Influence of astrocytes and OGD on mRNA expression of
tight junction molecules of cerebEND cells.
Normoxia OGD N-C6 OGD-C6
Claudin-3 1.00±0.06 1.01±0.11§ 0.73±0.05*# 0.82±0.07
Claudin-5 1.00±0.01 0.65±0.08*§ 1.04±0.04# 0.55±0.05*§
Claudin-12 1.00±0.05 1.05±0.05 1.02±0.09 1.17±0.09
Occludin 1.00±0.02 0.38±0.04*§ 1.08±0.11# 0.24±0.02*#§
ZO-1 1.00±0.05 0.74±0.04*§ 1.18±0.11# 0.67±0.07*§
Normoxia, cerebEND cells 4 h normoxia; OGD, cerebEND cells 4 h OGD; N-C6,
cerebEND cells 4 h normoxia with C6-medium; OGD-C6, cerebEND cells 4 h
OGD with C6-OGD medium. Data are presented as means ± s.e.m. (n = 8–10).
Statistical significance was labeled with *vs. normoxia, #significant vs. OGD,
§significant to N-C6 (p < 0.05, two-sided student’s t-test with same variances).
65% and to 55% (p < 0.05), respectively, whereas mRNA expres-
sion of claudin-12 was not affected by any of the treatments.
Similar to claudin-5, occludin was also significantly decreased by
OGD and OGD-C6 to 38% and to 24%, respectively (p < 0.05).
Finally, mRNA expression of ZO-1 was downregulated by OGD
and OGD-C6 to 74% and to 64% (p < 0.05). In comparison
to mRNA data western blots of total cell lysates revealed not
such a significant regulation of tight junction protein expres-
sion (Figure 2). Claudin-3 was decreased by OGD-C6 to 81%,
whereas claudin-5 protein expression was upregulated by N-C6
to 1.53-fold after 4 h treatment (p < 0.05). Claudin-12 was hardly
detectable on western blots. Similar to mRNA regulation occludin
was downregulated by OGD to 83% (p < 0.05), whereas ZO-1
was upregulated significantly by OGD and OGD-C6 to 1.34-fold
and to 1.36-fold, respectively (p < 0.05). In contrast to western
blots of total cell lysates, western blotting data with membrane
enriched Triton-X 100 fractions were similar to mRNA expres-
sion data of claudins. In case of claudin-3, a reduction was
only observed after N-C6 treatment (69%, p < 0.05). Claudin-
5 expression was decreased after OGD, N-C6 and OGD-C6 to 70,
67, and 70%, respectively (p < 0.05). On the contrary, occludin
expression of the 65 kDa band remained unchanged and ZO-
1 also increased after OGD to 1.27-fold. Western blotting data
proposed a change in localization of most tight junction pro-
teins, which was confirmed by immunofluorescence microscopic
images (Figure 3). Claudin-3 was significantly lost after treat-
ment with astrocyte factors (N-C6), whereas it formed distinct
continuous tight junction strands under other conditions. In
case of claudin-12, no continuous tight junction strands sur-
rounding the total cell were detected. OGD treatment seemed to
cause broader tight junction strands of claudin-5, occludin and
ZO-1, which could be due to a movement of tight junction pro-
teins apart from the cell-cell contacts. Images of OGD-C6 treated
cerebENDs showed a generally weaker staining density of tight
junction strands in comparison to normoxia samples.
INFLUENCE OF ASTROCYTES AND OGD ON EXPRESSION AND
FUNCTIONALITY OF ABC-TRANSPORTERS
mRNA expression of Abcb1a was upregulated by astrocyte factors,
OGD and OGD-C6 to 1.44-fold, 5.71-fold and 5.24-fold, respec-
tively (p < 0.05) (Table 2). On the contrary, mRNA expression
of Abcc4 was only signifcantly reduced by OGD-C6 treatment
to 66% (p < 0.05). In case of Abcg2, mRNA expression was
downregulated by OGD and OGD-C6 to 48 and 54%, respec-
tively (p < 0.05). Western blotting of total cell lysates for Abcb1
confirmed the trend of mRNA data (Figure 4). Abcb1 protein
was significantly upregulated by OGD (1.55-fold, p < 0.05) and
OGD-C6 (1.56-fold, p < 0.05). In contrast to mRNA expres-
sion, Abcc4 protein was also upregulated by OGD (1.39-fold,
p < 0.05) and OGD-C6 (1.44-fold, p < 0.05). In case of Abcg2
no significant regulation was found on the protein level after
4 h treatment. Immunofluorescence images confirmed that Abcg2
was the strongest expressed of the investigated Abc-transporters
in cerebENDs, followed by Abcc4 and Abcb1 (Figure 4).
To test transporter functionality, uptake assays were performed
for Abcb1, Abcc4, and Abcg2 with specific substrates (Calcein-
AM, Bodipy-FL-Prazosin, fluo-cAMP). No significant effects on
transporter functionalities were found after treatment for 4 h.
Therefore, uptake assays were carried out after 24 h normoxia
or 4 h OGD followed by 20 h normoxia. Verapamil increased
the uptake of Abcb1 substrate calcein-AM by 69.53 ± 4.08%
(n = 16) after normoxic treatment for 24 h (Figure 5). In con-
cordance to upregulated Abcb1 expression, Abcb1 functionality
was increased after OGD, N-C6 and OGD-C6 treatment result-
ing in a significant higher raise by verapamil by 118.92 ± 10.43%
(OGD, n = 16), by 125.26 ± 8.36 (N-C6, n = 8) and by 105.81
± 6.79% (OGD-C6, n = 8), respectively (p < 0.05). Uptake of
Abcc4 substrate fluo-cAMP was increased by MK571 by 90.91
± 5.14 (p < 0.05, n = 16) after 24 h normoxia. OGD treatment
did not change the amount of increased uptaken fluo-cAMP by
MK571 (89.21 ± 4.39, n = 16), whereas fluo-cAMP uptake dif-
ferences by MK571 were elevated by N-C6 and by OGD-C6 by
213.38 ± 8.16% and by 161.59 ± 11.65%, respectively (p < 0.05,
n = 8). In case of Abcg2, OGD reduced significantly the Ko143
increased uptake under normoxic conditions from 80.94± 2.71%
(n = 16) to 28.31 ± 5.56% (p < 0.05, n = 16), whereas N-C6
and OGD-C6 treatments did not lead to significant changes.
According to calcein-AM uptake data, western blotting showed
upregulation of Abcb1 protein after 4 h OGD and subsequent
20 h normoxia, after 24 h N-C6 and 24 h OGD-C6 to 1.64-fold,
to 1.45-fold and 1.52-fold (p < 0.05, n = 6), respectively. In case
of Abcc4, OGD, N-C6 and OGD-C6 increased Abcc4 protein
expression after 24 h to 1.59-fold (p < 0.05, n = 6), to 1.50-fold
(p < 0.05, n = 6) and to 1.86-fold (p < 0.05, n = 6). In contrast
to uptake data, Abgc2 western blots of total cell lysates revealed an
increase after OGD (1.32-fold) and N-C6 (1.22-fold, p < 0.05),
but interestingly a decrease after OGD-C6 (0.88-fold, p < 0.05).
To elucidate the reason for the mismatching of functionality and
Abcg2 protein expression data, western blots after 24 h treat-
ment were repeated with membrane protein enriched fractions
extracted with Triton-X 100. Protein expression data of Triton-X
100 fractions were similar to total protein lysates for Acbb1 and
Abcc4 and corresponded well to functional uptake data (Abcb1:
1.52-fold OGD-C6; Abcc4: 1.48-fold OGD, 1.90-fold OGD-C6;
p < 0.05, n = 6). In case of Abcg2, protein expression was signif-
icantly decreased by OGD to 0.73 ± 0.12-fold (p < 0.05, n = 4),
whereas N-C6 nor OGD-C6 showed no significant differences in
comparison to the normoxic control.
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FIGURE 2 | Influence of 4h oxygen/glucose deprivation (OGD) treatment
and presence of astrocyte soluble factors on protein expression of tight
junction proteins claudin-3, claudin-5, occluding, and ZO-1 of cerebEND
cells. On the left side results of densitometric analysis derived from western
blots of total protein cell lysates as well as of Triton-X 100 membrane
enriched fractions are presented, on the right side according representative
western blot images are depicted. N, cerebEND normoxic control; OGD,
cerebENDs treated under OGD conditions for 4 h; N−C6 or N+C6,
cerebENDs treated for 4 h with C6 conditioned medium derived from C6 cells
which were treated under normoxic control conditions for 4 h; OGD−C6 or
OGD+C6, cerebENDs treated for 4 h OGD with C6 conditioned medium
derived from C6 cells which were treated under OGD conditions for 4 h.
Statistical significance was labeled with ∗(p < 0.05, two-sided student’s
t-test with same variances). Data are presented as means ± s.e.m. (n = 4–6).
INFLUENCE OF ASTROCYTES AND OGD ON EXPRESSION AND
FUNCTIONALITY OF MMPs
Matrixmetalloproteinases (MMPs) play a pivotal role in the
degradation processes of basal lamina as well as of tight junc-
tion proteins at the blood-brain barrier during ischemic insults
(reviewd in Jin et al., 2010). Therefore, changes ofMMP2,MMP3,
and MMP9 as well as from their inhibitors TIMP1 and TIMP3
of cerebENDs cells were investigated. Results were summarized
in Table 3. Four hours of OGD significantly decreased TIMP-
1 mRNA expression 88%, whereas increased TIMP-3 mRNA
1.39-fold (p < 0.05, n = 6). Addition of astrocyte factors (N-C6)
increased MMP-3 expression 3.93-fold and TIMP-1 expression
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FIGURE 3 | Representative immunofluorescence images of tight
junction proteins of cerebENDs treated for 4h under normoxic or
OGD conditions in the presence or absence of astrocyte soluble
factors. Normoxia, cerebEND normoxic control for 4 h; OGD, cerebENDs
treated under OGD conditions for 4 h; N-C6, cerebENDs treated for 4 h
with C6 conditioned medium derived from C6 cells which were treated
under normoxic control conditions for 4 h; OGD-C6, cerebENDs treated
for 4 h OGD with C6 conditioned medium derived from C6 cells which
were treated under OGD conditions for 4 h. White arrows indicate lost
tight junctions strands in case of claudin-3 N-C6, broadened tight
junctions strands after OGD and OGD-C6 in case of claudin-3, claudin-5,
and occludin, broadening and leaks in tight junction strands of ZO-1
OGD and OGD-C6 and non-continuous tight junction strands in case of
claudin-12.
1.47-fold, but decreased TIMP-3 expression to 79% (p < 0.05,
n = 8). In case of OGD treatment with astrocyte factors (OGD-
C6), MMP-2 expression was lowered to 92%, whereas TIMP-
1 was upregulated to 1.39-fold (p < 0.05, n = 8). In order to
test the functional relevance of these complex regulations, total
enzyme activity of MMPs in medium supernatants was mea-
sured (Figure 6). Four hours OGD treatment of cerebEND cells
significantly increased MMP activity to 164.31 ± 36.01% com-
pared to normoxic control (100.00 ± 27.08%, p < 0.05, n = 8).
Four hours of normoxic incubation of cerebENDs with astro-
cyte medium supernatants, which was incubated for 4 h under
normoxic conditions before, led to an increase to 587.60 ±
105.47%, whereas addition of medium supernatants of OGD-
treated astrocytes increased MMP-activity still significantly, but
only to 446.07 ± 14.35% (p < 0.05). Analysing MMP-activity
of C6 supernatants revealed a distinct higher activity for C6
supernatants in comparison to that obtained from cerebEND
cells. Normoxic treated C6 cells secreted a MMP activity of
2694.62 ± 383.77% (p < 0.05, n = 14) in comparison to nor-
moxic control of cerebENDs. OGD-treatment of C6 cells resulted
in a significant decrease to 1271.67 ± 221.88% (p < 0.05, n =
12). Considering these MMP-activity start values for cerebEND
incubation with C6 supernatants, a net increase of MMP-
activity between N-C6 and OGD-C6 treatment of cerebEND cells
of 60.86% could be calculated. In summary, OGD treatment
increased MMP activity released by cerebENDs regardless of the
presence of astrocytes.
INFLUENCE OF ASTROCYTES AND OGD ON EXPRESSION AND
FUNCTIONALITY OF t-PA
t-PA activity plays a major role in proteases cascades responsible
for plasmin and MMP activation and following degradation of
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Table 2 | Influence of astrocytes and OGD on mRNA expression of
Abc-transporters of cerebEND cells.
Normoxia OGD N-C6 OGD-C6
Abcb1a 1.00±0.07 1.44±0.17*§ 5.71±0.46*# 5.25±0.72*#
Abcc4 1.00±0.02 0.89±0.15 1.07±0.06 0.66±0.02*#§
Abcg2 1.00±0.03 0.48±0.03*§ 0.89±0.06# 0.54±0.05*§
Normoxia, cerebEND cells 4 h normoxia; OGD, cerebEND cells 4 h OGD; N-C6,
cerebEND cells 4 h normoxia with C6-medium; OGD-C6; cerebEND cells 4 h
OGD with C6-OGD medium. Data are presented as means ± s.e.m. (n = 8–10).
Statistical significance was labeled with *vs. normoxia, #significant vs. OGD,
§significant to N-C6 (p < 0.05, two-sided student’s t-test with same variances).
the basal lamina. Therefore, expression and functionality of t-PA
and its inhibitor PAI-1 were assessed under normoxic and OGD
conditions. Figure 7A shows an upregulation of t-PA mRNA
expression in cerebEND cells by OGD treatment to 4.40-fold, by
N-C6 to 1.36-fold and by OGD-C6 to 5.81-fold (p < 0.05, n = 6–
8), whereas PAI-1 remained unregulated by any of the treatments
(Figure 7B). To assess functional consequences of regulated t-PA,
t-PA activity was measured in medium supernatants of cerebEND
cells. Four hours of OGD significantly increased t-PA activity
to 161.90 ± 8.17% in comparison to 100 ± 9.92% of the nor-
moxia control (p < 0.05). N-C6 treatment raised t-PA activity to
169.42 ± 13.34%, which was further elevated to 226.66 ± 8.83%
by OGD-C6 (p < 0.05). Interestingly, t-PA activity of medium
supernatants derived from treated C6 cells decreased after OGD
from 106.64 ± 22.61% to 47.11 ± 13.68% (p < 0.05, Figure 7C).
These C6-medium supernatents were subsequently used to incu-
bate cerebEND cells. Including the t-PA activity starting values
of the C6-medium supernatants in the comparison of N-C6 vs.
OGD-C6 data resulted in a real net t-PA activity increase of about
116% caused by cerebENDs.
INFLUENCE OF ASTROCYTES AND OGD ON SURFACE MORPHOLOGY OF
BRAIN ENDOTHELIAL CELLS
To evaluate whether different treatments changed the surface
structure of cerebEND cells, their surface was analyzed at the
nanoscale using atomic force microscopy (AFM). To objectively
quantify the surface texture, a novel method was applied (nAnos-
tic), which detects structures protruding from the mean surface
level via computer vision. Interestingly, OGD treatment revealed
a significant reduction of protruding nano-objects on the surface
from 315± 18 to 196± 23 (p < 0.05, n = 20, Figure 8). Addition
of astrocyte factors (N-C6) also reduced the number of identi-
fied nanostructures to 255 ± 22, which was further decreased by
OGD-C6 to 163 ± 18 objects (p < 0.05).
DISCUSSION
Ischemic insults such as stroke or traumatic brain injury induce
changes of several facets of the blood-brain barrier (BBB). This
comprises opening of the paracellular sealing by disorganization
and disruption of tight junctions which thereafter contributes to
vasogenic edema formation and worsened stroke outcome. But
also Abc-transporter expression and functionality are changed
leading to altered defense and protection against xenobiotics
(drugs) as well as endogenous substrates (hormones). In addition
to edema formation, this causes distinct disturbances in brain
homeostasis and consequently damage of e.g., astrocytes or neu-
rons via penetrated blood-born proteins (albumin) or changed
ion concentration. Moreover, pharmacokinetics of drugs are
influenced by dysregulated Abc-transporter activities. Therefore,
it is of immense importance to unravel the complex underly-
ing mechanisms to understand the pathology and to be able to
develop novel therapeutic strategies.
In this context, it is known that astrocytes play a pivotal
role during stroke pathogenesis. In the non-pathological status
astrocytes are crucial for the maintenance of BBB characteris-
tics (Janzer and Raff, 1987; Neuhaus et al., 1991; Deli and Joó,
1996; Ronaldson and Davis, 2012). They are suggested to regulate
BBB permeability, water and ion exchange (Ballabh et al., 2004;
Abbott et al., 2006; Mathiisen et al., 2010). In case of ischemic
insults, the response of astrocytes is multifaceted. Astrocyte end
feet cover over 95% of the brain capillary surface on the brain
side. The injury of astrocytes results in a compromised BBB. Their
local loss leads to a disassembly of the tight junction network and
decreased expression of tight junction proteins such as occludin,
claudin-5 or ZO-1. This correlates directly to paracellular leak-
iness (Willis et al., 2004, 2013; Shin et al., 2013). In addition,
ischemia injured/activated astrocytes secrete chemokines (MCP-
1, Rantes), pro—and anti-inflammatory cytokines (IL-1α, IL-1β,
TNFα, interferon-γ) and growth factors (VEGF, bFGF, TGF-β).
These molecules are known to directly activate processes at the
brain endothelium to disrupt the BBB, promote angiogenesis or
regulate transporters at the BBB (Lau and Yu, 2001; Lee et al.,
2007; Doyle et al., 2010; Strecker et al., 2011; Vangilder et al., 2011;
Ronaldson and Davis, 2012). Although these relations are known,
no comprehensive in vitro study exist to unravel the effects of
astrocytes, OGD or their combination on brain endothelial cells.
Consequently, we studied the influence of astrocytes and OGD on
an established blood-brain barrier (BBB) in vitromodel based on
murine cerebEND cells (Silwedel and Förster, 2006). CerebENDs
represent an adequate BBB cell culture model forming signif-
icant tight monolayers with high TEER values comparable to
models based on mouse primary brain endothelial cells (Silwedel
and Förster, 2006; Takeshita et al., 2014). Moreover, cerebEND
cells were successfully used for OGD studies and responded
to TNFα-stimulus with a rapid increase of paracellular perme-
ability (Silwedel and Förster, 2006; Neuhaus et al., 2012a). In
the presented study permeability coefficients for the paracellu-
lar marker fluorescein were between 0.4–0.9∗10−3 cm/min, which
was in a similar range of other paracellular markers with a sim-
ilar molecular weight (sucrose, Lucifer yellow) used for OGD
in vitro studies with primary brain endothelial cells (Mysiorek
et al., 2009). This range of permeability for such integrity markers
(below 1∗10−3 cm/min) was reported as adequate for validated
BBB in vitro models in terms of in vitro/in vivo correlations
(Lundquist et al., 2002; Culot et al., 2008; Mysiorek et al., 2009).
As first important parameter we have investigated the func-
tionality of the physical barrier by measuring TEER and flu-
orescein permeability directly after OGD treatments. In exper-
imental models of focal cerebral ischemia it was shown that
sucrose, a vascular marker with low molecular weight, was able to
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FIGURE 4 | Influence of 4h oxygen/glucose deprivation (OGD)
treatment and presence of astrocyte soluble factors on protein
expression of Abc-transporters Abcb1, Abcc4, and Abcg2 of cerebEND
cells. Immunofluorescence images of cerebEND cells under normoxic
conditions show the distribution of Abcb1, Abcc4, and Abcg2. In the
middle, results of densitometric analysis derived from western blots of
total protein cell lysates are presented, on the right side according
representative western blot images are depicted. N, cerebEND normoxic
control; OGD, cerebENDs treated under OGD conditions for 4 h; N−C6 or
N+C6, cerebENDs treated for 4 h with C6 conditioned medium derived
from C6 cells which were treated under normoxic control conditions for
4 h, OGD−C6 or OGD+C6, cerebENDs treated for 4 h OGD with C6
conditioned medium derived from C6 cells which were treated under OGD
conditions for 4 h. Statistical significance was labeled with ∗(p < 0.05,
two-sided student’s t-test with same variances). Data are presented as
means ± s.e.m. (n = 4-6).
permeate into the ipsilateral parenchymal hemisphere after tran-
sient middle cerebral artery occlusion (tMCAO) (Pfefferkorn and
Rosenberg, 2003). Moreover, 2 h after tMCAO leaks in the BBB
were found even for bigger molecules such as Evans Blue-albumin
complexes (>60,000Da) indicating a rapid opening of the BBB
after stroke (Jiao et al., 2011). In concordance to this, we were
able to show a significant BBB breakdown after OGD treatment
in our in vitro model. Moreover, loss of barrier functionality was
significantly increased by the presence of astrocytes during the
OGD-treatment. Our data confirmed a previous OGD-study with
a BBB co-culture model consisting of primary mouse endothelial
and rat glial cells in which the presence of glial cells was nec-
essary to disrupt the barrier significantly (Brillault et al., 2002;
Mysiorek et al., 2009). In this context, vascular endothelial growth
factor (VEGF) could be one major factor for BBB breakdown in
our model. It was shown that VEGF was significantly upregu-
lated in astrocytes after OGD or hypoxia, and it was postulated
that this is responsible for BBB damage (Redzic et al., 2013).
With regard to our model, C6 cells secreted significant amounts
of VEGF which was further upregulated via hypoxia (Boveri
et al., 2005; Yeh et al., 2008). Under our experimental conditions
OGD increased mRNA levels of VEGF in C6 cells approxi-
mately two-fold (data not shown). In this context, it should be
noted that cerebEND layers co-cultured with C6 cells exhibited
lower TEER values in comparison to the mono-culture set-up
before OGD experiments (presumably due to high basal VEGF
levels and MMP activity (see Figure 6) in C6 medium super-
natants). This fact has to be considered for data interpretation
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FIGURE 5 | Influence of 4h oxygen/glucose deprivation (OGD) treatment
with subsequent 20h reoxygenation phase and presence of astrocyte
soluble factors on Abc-transporter activity and protein expression. On
the left side results of uptake assays with specific substrates for Abcb1
(calcein-AM), Abcc4 (fluo-cAMP), and Abcg2 (Bodipy-FL-prazosin) are
presented. In the middle densitometric analysis derived from western blots
of total protein cell lysates as well as Triton-X 100 membrane enriched
fractions are shown, on the right side according representative western blot
images are depicted. N, cerebEND normoxic control; OGD, cerebENDs
treated under OGD conditions for 4 + 20 h reoxygenation/renutrition; N−C6
or N+C6, cerebENDs treated for 24 h with C6 conditioned medium derived
from C6 cells which were treated under normoxic control conditions for 4 h;
OGD−C6 or OGD+C6, cerebENDs treated for 4 h OGD with C6 conditioned
medium derived from C6 cells which were treated under OGD conditions for
4 h with a subsequent incubation of cerebENDs for 20 h with N−C6 medium.
Statistical significance was labeled with ∗(p < 0.05, two-sided student’s
t-test with same variances). Data are presented as means ± s.e.m. (n = 8–16
for uptake assays, n = 4–6 for protein expression data).
Table 3 | Influence of astrocytes and OGD on mRNA expression of
matrixmetalloproteinases MMP-2, -3, and -9, and TIMP-1 and TIMP-3
of cerebEND cells.
Normoxia OGD N-C6 OGD-C6
MMP-2 1.00±0.02 0.95±0.09 1.11±0.06 0.92±0.03*§
MMP-3 1.00±0.03 0.88±0.14 3.93±1.07*# 3.12±1.12
MMP-9 1.00±0.02 0.95±0.17 0.89±0.19 1.10±0.22
TIMP-1 1.00±0.01 0.88±0.04*§ 1.47±0.18*# 1.39±0.15*#
TIMP-3 1.00±0.05 1.39±0.07*§ 0.79±0.04*# 1.02±0.09#§
normoxia, cerebEND cells 4 h normoxia; OGD, cerebEND cells 4 h OGD; N-C6,
cerebEND cells 4 h normoxia with C6-medium; OGD-C6, cerebEND cells 4 h
OGD with C6-OGD medium. Data are presented as means ± s.e.m. (n = 6–
8). Statistical significance was labeled with *vs. normoxia, #significant vs. OGD,
§significant to N-C6 (p < 0.05, two-sided student’s t-test with same variances).
of fluorescein experiments (Figure 1B). In comparison to nor-
moxia controls, N-C6 (normoxia+C6 cells) treatment resulted in
increased TEER, but also apparently contradictory in elevated flu-
orescein permeability. TEER was determined before and after the
experiments, whereas fluorescein was only measured at the end of
the tests. Hence, fluorescein data reflected the absolute tightness
status after the incubation periods, whereas TEER data presented
the relative changes between before and after the treatments.
Consequently, fluorescein permeability of N-C6 (normoxia+C6
cells) was higher than normoxic control (Figure 1B), because
basal tightness of co-cultured cerebENDs was lower in the begin-
ning of the OGD-experiment in comparison to mono-cultured
cerebENDs. However, comparison of normoxic and OGD treated
co-cultured cerebEND cells (normoxia+C6 cells vs. OGD+C6)
revealed a very significant increase of fluorescein permeability
after OGD-treatment, confirmed corresponding TEER data and
thus demonstrated the additionally deleterious effects of astro-
cytes on BBB breakdown in vitro.
Increased BBB permeability for paracellular markers (sucrose,
dextrans, Evans Blue-albumin) was directly correlated with
changed expression or localization of tight junction proteins such
as claudin-5, occludin or ZO-1 in vivo (Witt et al., 2003; Jiao et al.,
2011). Redistribution of tight junction molecules were detected
even after 2 h of reperfusion in a tMCAO rat model (Jiao et al.,
2011). In concordance to this, OGD decreased mRNA expression
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FIGURE 6 | Influence of 4h oxygen/glucose deprivation (OGD)
treatment and presence of astrocyte soluble factors on total MMP
activity in medium supernatants. C6-medium, supernatants of C6 cells
after 4 h normoxia; C6-OGD medium, supernatants of C6 cells after 4 h
OGD; normoxia, supernatants of cerebEND cells after 4 h normoxia; OGD,
supernatants of cerebEND cells after 4 h OGD; N-C6, supernatants of
cerebEND cells after 4 h normoxia treated with C6-medium; OGD-C6,
supernatants of cerebEND cells after 4 h OGD treated with C6-OGD
medium. Statistical significance was labeled with ∗(p < 0.05, two-sided
student’s t-test with same variances). Data are presented as means ±
s.e.m. (n = 8–19).
of claudin-5, occludin and ZO-1 in our model significantly.
Interestingly, presence of astrocytes did not influence mRNA lev-
els of these tight junction proteins. Moreover, protein expression
of tight junction proteins in total cell lysates was not strongly
reduced. This was in concordance to results of Engelhardt et al.
(2014) who showed that total protein expression of claudin-5
(up to 48 h), occludin (up to 48 h) and ZO-1 (up to 8 h) were
not decreased after several hours of hypoxia (1% O2) although
TEER was reduced. Similar to our analysis, immunofluorescence
images uncovered a delocalization of the investigated tight junc-
tion proteins. They and others reported that increased tyrosine-
phosphorylation of tight junction molecules such as occludin
or claudin-5 occurred which probably caused the disappear-
ance of tight junction molecules from the cell boarders (András
et al., 2007; Engelhardt et al., 2014). In this context, western
blots of membrane enriched Triton-X 100 fractions confirmed
the reduction of claudin-5 by OGD in our model and supported
mRNA data as well as immunofluorescence images. Few data exist
about claudin-3 and stroke. A recent study showed downregu-
lated claudin-3 after 24 h after the surgery in a mouse model
of intracerebral hemorrhage (Krafft et al., 2013). In our model
expression of claudin-3 was not changed after 4 h of OGD treat-
ment. Other claudins (claudin-1, claudin-12) are thought to be
not significantly important for the barrier function in our model.
Claudin-1 was hardly detectable by western blotting and was not
found at cell-cell boarders on immunofluorescence images (data
not shown). Claudin-12 formed non-continuous tight junction
FIGURE 7 | Influence of 4 h oxygen/glucose deprivation (OGD)
treatment and presence of astrocyte soluble factors on mRNA
expression of t-PA (A) and PAI-1 (B) of cerebENDs and t-PA activity in
medium supernatants (C). For mRNA expression data: N, cerebEND
normoxic control; OGD, cerebENDs treated under OGD conditions for 4 h;
N-C6, cerebENDs treated for 4 h with C6 conditioned medium derived from
C6 cells which were treated under normoxic control conditions for 4 h,
(Continued)
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FIGURE 7 | Continued
OGD-C6, cerebENDs treated for 4 h OGD with C6 conditioned medium
derived from C6 cells which were treated under OGD conditions for 4 h; for
t-PA activity data: C6-medium, supernatants of C6 cells after 4 h normoxia;
C6-OGD medium, supernatants of C6 cells after 4 h OGD; normoxia,
supernatants of cerebEND cells after 4 h normoxia; OGD, supernatants of
cerebEND cells after 4 h OGD; N-C6, supernatants of cerebEND cells after
4 h normoxia treated with C6-medium; OGD-C6, supernatants of cerebEND
cells after 4 h OGD treated with C6-OGD medium. Statistical significance
was labeled with ∗(p < 0.05, two-sided student’s t-test with same
variances). Data are presented as means ± s.e.m. (n = 6–8 for mRNA
analysis, n = 3–13 for t-PA activity).
strands according to the postulation that claudin-12 itself can not
form tight junctions (Piontek et al., 2011).
As next key property of the BBB, the expression and function-
ality of ABC-transporters were investigated. Few in vivo data are
available about the regulation of ABC-transporters after stroke.
Most of the reports showed an increase of expression as well as
functionality of Abcb1 (Spudich et al., 2006; Lazarowski et al.,
2007; Ueno et al., 2009). On the contrary, Dazert et al. (2006)
found no differences in the regulation of Abcb1 on the mRNA
level in his rat stroke model. In our model Abcb1 was signif-
icantly upregulated by C6 cells under normoxic conditions as
well as OGD treatment. This was in concordance to other studies
revealing that primary astrocytes as well as C6 cells were able to
increase Abcb1 expression and functionality of brain endothelial
cells (El Hafny et al., 1997; Gaillard et al., 2000; Berezowski et al.,
2004). In case of Abcg2 few data exist about its regulation in vivo
after stroke. For example, Dazert et al. (2006) published that
Abcg2 was significantly upregulated at mRNA level after 14 days
of reperfusion. In our model we were able to show for the first
time that Abcg2 was downregulated by OGD in brain endothe-
lial cells. In concordance to our in vitro data, own in vivo stroke
studies revealed that Abcg2 protein expression of total brain sam-
ples was significantly decreased after 1 h tMCAO followed by 24 h
reperfusion in male C57Bl/6 mice (unpublished data). Previous
reports showed that inflammatory processes were mediated by
pro-inflammatory cytokines such as TNFα within 2–6 h after the
ischemic insult (Ronaldson and Davis, 2012). In this context and
completely concordant to our expression as well as functionality
data, it was shown that TNFα increased expression of ABCB1, but
decreased expression of ABCG2 in a human BBB in vitro model
(Poller et al., 2010). However, related to our in vitro data it can
not be excluded that Abcg2 expression and functionality would
be increased after a longer reperfusion phase after OGD as shown
by Dazert et al. (2006).
Several studies reported that matrix metalloproteinases
(MMPs) and tissue-type plasminogen activator (tPA) were
involved in BBB disruption during stroke (Adibhatla andHatcher,
2008; Bauer et al., 2010). As mentioned before, MMPs could
degrade tight junction proteins claudin-5 and occludin as well
as components of the basal lamina such as fibronectin, laminin
and collagen leading to a disintegrated BBB and brain edema
(Adibhatla and Hatcher, 2008; Cunningham et al., 2005; Yang
and Rosenberg, 2011). Previously, MMP-2, MMP-3 and MMP-
9 were shown to be the major MMPs in BBB disruption with
a time-dependent activation and a very complex regulation (Jin
et al., 2010). Moreover, MMP-9 levels were significantly increased
after acute stroke in patients of a clinical study (Brouns et al.,
2011). In our model, no significant regulation was found on
the mRNA level of the investigated MMPs by OGD. However,
according to the literature enzymatic activity of total MMPs
of cerebEND cells was significantly upregulated by OGD in
our model. This suggested that the MMP regulation took place
mainly on the protein level. Moreover, recently Lenglet et al.
(2014) proved the relevance of active MMP-1, MMP-10 and
MMP-13 during stroke. These MMPs were not analyzed on the
mRNA level in the presented study. Furthermore, protease t-PA
can induce MMP-9 mediated BBB disruption and increase the
MMP-1/TIMP-2, MMP-2/TIMP-2, MMP-8/TIMP-2 and MMP-
9/TIMP-2 ratios in the hyperacute phase of reperfusion (Wang
et al., 1998; Tsuji et al., 2005; Lenglet et al., 2014). In our model,
expression as well as activity of t-PA of cerebEND cells was sig-
nificantly upregulated by OGD according to the literature and
can therefore also contribute to the observed barrier breakdown
in vitro. Interestingly, in contrast to MMP activity, presence
of astrocyte factors increased t-PA activity of cerebEND cells
after OGD.
The novel Nanostic-AFM method enabled us to detect and
quantify changes of brain endothelial cells after OGD treatments
via a morphological approach even at the nanometer scale. Of
note, the topographical alterations focus on local height dis-
tributions which are non-detectable for light microscopy. With
the brain endothelial cells investigated here, OGD significantly
reduced the number of microvilli-like objects. In epithelial cell
layers the number of counted nanostructures (objects) on the
cell surface was related to the cytoskeletal organization and
the degree of cellular differentiation (Thoelking et al., 2010).
In brain endothelial cells tight junction proteins are connected
to the cytoskeleton (Abbott et al., 2006; Ronaldson and Davis,
2012). In our model, the link between the number of objects to
an underlying cytoskeletal remodeling has to be shown in fur-
ther studies. However, it could be hypothesized that a decreased
number of nanostructures could be associated to the already
shown redistribution of tight junction proteins and loss of barrier
after OGD.
In summary, we were able to show that the influence of astro-
cytes in our BBB in vitro stroke model is of immense importance
comprising the physical and the transport barrier as well as major
BBB damaging proteases. Consequently, we would recommend
to include astrocytes in BBB in vitro stroke models according to
the concept of the neurovascular unit and its role during cerebral
ischemia (Berezowski et al., 2012). However, it has to be pointed
out that the brain endothelium in vivo is additionally regulated by
blood flow and several other cell types of its microenvironment
(pericytes, microglia, oligodendrocytes, blood cells). In vivo pro-
cesses causing BBB disruption and repair during and after stroke
take place in a complex regulatory network which is not possible
to be simulated entirely in our model. Also, we can not exclude
that results obtained from a BBBmodel with a 3D capillary archi-
tecture based on the same cells as used in this study would differ
from the presented ones. Therefore, future studies with in vivo
stroke models have to elucidate concordance and relevance of our
in vitro findings.
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FIGURE 8 | Nanoscale surface topography analysis (nAnostic). CerebEND
cells after 4 h oxygen/glucose-deprivation (OGD) and/or incubation with
astrocyte conditioned medium were fixed by addition of glutardialdehyde (1%
final conc.) and subjected to topography recording through atomic force
microscopy (AFM) in buffer fluid—without any drying or labeling procedure.
Quantitative analysis of protruding nano-objects is performed by computer
vision. Shown are 3D-overviews of 50μm (upper row), 20μm raw data as
taken for quantitative analysis (2nd row), a mask of identified nano-objects in
green (3rd row) and the overlay of the two latter (lower row). Normoxia,
cerebEND cells 4 h normoxia; OGD, cerebEND cells 4 h OGD; N-C6,
cerebEND cells 4 h normoxia with C6-medium; OGD-C6, cerebEND cells 4 h
OGD with C6-OGD medium. Statistical significance was indicated with an
∗(p < 0.05 two-sided student’s t-test with same variances). Data are
presented as means ± s.e.m. of n = 20 images of (20μm)2 area.
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